scholarly journals Gene Therapy of a Rat Follicular Thyroid Carcinoma Model with Adenoviral Vectors Transducing Murine Interleukin-12

Endocrinology ◽  
2003 ◽  
Vol 144 (4) ◽  
pp. 1393-1398 ◽  
Author(s):  
Rusheng Zhang ◽  
Leslie J. DeGroot
Keyword(s):  
Gene Therapy ◽  
Thyroid Carcinoma ◽  
Follicular Thyroid Carcinoma ◽  
Adenoviral Vectors ◽  
Interleukin 12

Gene Therapy of Anaplastic Thyroid Carcinoma with a Single-Chain Interleukin-12 Fusion Protein

2003 ◽  
Vol 14 (18) ◽  
pp. 1741-1751 ◽  
Author(s):  
Yufei Shi ◽  
Ranjit S. Parhar ◽  
Minjing Zou ◽  
Essa Baitei ◽  
George Kessie ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Thyroid Carcinoma ◽  
Fusion Protein ◽  
Anaplastic Thyroid Carcinoma ◽  
Interleukin 12 ◽  
Single Chain

scholarly journals sFlt-1 Gene Therapy of Follicular Thyroid Carcinoma

Endocrinology ◽  
2004 ◽  
Vol 145 (2) ◽  
pp. 817-822 ◽  
Author(s):  
Caisheng Ye ◽  
Chong Feng ◽  
Shenming Wang ◽  
Kent Z. Q. Wang ◽  
Nancy Huang ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Thyroid Carcinoma ◽  
Tumor Growth ◽  
Tumor Progression ◽  
Tumor Angiogenesis ◽  
Follicular Thyroid Carcinoma ◽  
Umbilical Vein ◽  
Control Treatment ◽  
Vegf Receptor ◽  
Antitumor Effects

Abstract Tumor progression largely depends on blood supply and neovessel formation, and angiogenesis is emerging as a promising target for cancer therapy. Vascular endothelial growth factor (VEGF), a major proangiogenic molecule, stimulates angiogenesis via promoting endothelial proliferation, survival and migration. VEGF has been found to be up-regulated in various types of tumors and to be associated with tumor progression and poor prognosis. Inhibition of VEGF or its signaling pathway has been shown to suppress tumor angiogenesis and tumor growth. In the present study, we tested the antiangiogenic and antitumor effects of soluble VEGF receptor-1 [soluble Flt (sFlt)-1] on the growth of follicular thyroid carcinoma (FTC). We constructed a 293 embryonic kidney cell line (293-Flt1–3d) that expresses sFlt-1, which is composed of the first three extracellular domains of Flt-1. The 293-Flt1–3d cells inhibited the in vitro growth of human umbilical vein endothelial cells in a paracrine manner. The in vivo antitumor and antiangiogenic activities of the 293-Flt1–3d cells were tested. When 293-Flt1–3d cells were inoculated at a site remote to the FTC-133 tumor transplant, the growth of FTC-133 tumors were inhibited by 70.37%, as compared with the control treatment with 293 cells expressing control gene LacZ. Immunohistochemical analysis of microvessel densities in treated tumors demonstrated that 293-Flt1–3d cells robustly suppressed intratumoral angiogenesis. Our data suggest that a mammalian cell-mediated approach could effectively deliver sFlt-1 gene therapy and inhibit tumor angiogenesis and tumor growth.

622: Intravesical Interleukin-12 Gene Therapy in an Orthotopic Bladder Cancer Model

2006 ◽  
Vol 175 (4S) ◽  
pp. 200-201
Author(s):  
Minoru Horinaga ◽  
Kelley Harsch ◽  
Ryuichi Fukuyama ◽  
Warren Heston ◽  
William Larchian
Keyword(s):  
Gene Therapy ◽  
Bladder Cancer ◽  
Interleukin 12 ◽  
Cancer Model ◽  
Bladder Cancer Model

Mutations and somatic changes in the genotype of rs2910164 in pre-miR146a are frequent in follicular thyroid carcinoma

2013 ◽  
Author(s):  
Eleonora Vighi ◽  
Elisa Pignatti ◽  
Luca Roncati ◽  
Vincenzo Rochira ◽  
Elda Kara ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Follicular Thyroid Carcinoma

Brain metastasis from follicular thyroid carcinoma as first manifestation of the disease

2016 ◽  
Author(s):  
Rosa Marquez-Pardo ◽  
Lourdes Garcia-Garcia-Doncel ◽  
Baena-Nieto M Gloria ◽  
Manuel Cayon-Blanco ◽  
Rosario Lopez-Velasco ◽  
...  
Keyword(s):  
Brain Metastasis ◽  
Thyroid Carcinoma ◽  
Follicular Thyroid Carcinoma
Sign in / Sign up

Export Citation Format

Share Document